Form S-1MEF AYTU BIOSCIENCE, INC
As filed with the Securities and Exchange Commission on March 1, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
AYTU BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 47-0883144 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
373 Inverness Parkway
Suite 206
Englewood, Colorado 80112
(720) 437-6580
(Address, including zip code and telephone number, including
area code, of registrant’s principal executive offices)
Joshua R. Disbrow
Chief Executive Officer
373 Inverness Parkway
Suite 206
Englewood, Colorado 80112
Telephone: (720) 437-6580
(Name, address, including zip code and telephone number, including area code, of agent for service)
Copies to:
Gregory Sichenzia, Esq. Marcelle Balcombe, Esq. Jeff Cahlon, Esq. Sichenzia Ross Ference Kesner LLP 1185 Avenue of the Americas, 37th Floor New York, New York 10036 (212) 930-9700 |
Anthony J. Marsico, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 666 Third Avenue New York, New York 10017 (212) 935-3000
|
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of the registration statement.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), check the following box. ☒
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-222994
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☐ | Accelerated filer ☐ | |
Non-accelerated filer ☐ (Do not check if a smaller reporting company) |
Smaller reporting company ☒ | |
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered | Proposed Maximum Aggregate Offering Price(1)(2) |
Amount of Registration Fee |
||||||
Class A Units consisting of: | $ | ___ | $ | ___ | ||||
(i) Common Stock, par value $0.0001 per share | ||||||||
(ii) Warrants to purchase Common Stock | ||||||||
Class B Units consisting of | $ | ___ | $ | __ | ||||
(i) Series B Convertible Preferred Stock, par value $0.0001 per share | ||||||||
(ii) Warrants to purchase Common Stock | ||||||||
(iii) Common Stock issuable upon conversion of the Series B Convertible Preferred Stock | ||||||||
Common Stock issuable upon exercise of warrants | ___ | __ | ||||||
Total | 5,060,000 | 629.97 |
(1) Represents only the additional dollar amount of securities being registered and includes the additional dollar amount of securities that the underwriters have the option to purchase to cover over-allotments, if any. Does not include the securities that the registrant previously registered on the registration statement on Form S-1 (File No. 333-222994).
(2) Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Based on the public offering price per share.
THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE UPON FILING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH RULE 462(B) UNDER THE SECURITIES ACT.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This Registration Statement is being filed with respect to the registration of additional securities of Aytu BioScience, Inc. (the “Registrant”), pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the Registration Statement on Form S-1 (File No. 333-222994) filed by the Registrant with the Securities and Exchange Commission, as amended, declared effective on March 1, 2018, including exhibits and power of attorney thereto, are incorporated by reference in this Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Englewood, State of Colorado, on March 1, 2018.
AYTU BIOSCIENCE, INC. | ||
By: | /s/ Joshua R. Disbrow | |
Joshua R. Disbrow | ||
Chairman and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | |||
/s/ Joshua R. Disbrow | Chairman and Chief Executive Officer | March 1, 2018 | |||
Joshua R. Disbrow | (Principal Executive Officer) | ||||
/s/ David A. Green | Chief Financial Officer | March 1, 2018 | |||
David A. Green | (Principal Financial and Accounting Officer) | ||||
/s/ Michael Macaluso * | Director | March 1, 2018 | |||
Michael Macaluso | |||||
/s/ Gary Cantrell * | Director | March 1, 2018 | |||
Gary V. Cantrell | |||||
/s/ Carl C. Dockery * | Director | March 1, 2018 | |||
Carl C. Dockery | |||||
/s/ John Donofrio, Jr. * | Director | March 1, 2018 | |||
John A. Donofrio, Jr. | |||||
* By: | /s/ Joshua R. Disbrow | ||||
Attorney-in-fact |
EXHIBIT INDEX
Exhibit 5.1
March 1, 2018 Aytu BioScience, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112
Re: Registration Statement on Form S-1 Filed Pursuant to Rule 462(b)
Ladies and Gentlemen:
We refer to the above-captioned registration statement on Form S-1 (the “Registration Statement”), filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Act”), filed by Aytu BioScience, Inc. a Delaware corporation (the “Company”), with the Securities and Exchange Commission, which incorporates by reference the Registration Statement on Form S-1 (File No. 333-222994), as amended, which was declared effective on March 1, 2018.
The Registration Statement pertains to an underwritten offering by the Company of the Securities (as defined below), including Securities which may be issued on the exercise of the underwriters’ over-allotment option. As used herein, the term “Securities” includes: (i) Class A Units, consisting of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to each purchase one share of Common Stock (each, a “Warrant”, and collectively, the “Warrants”); (ii) Class B Units (collectively with the Class A Units, the “Units”), consisting of shares of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred”) convertible into Common Stock, and Warrants, (iii) shares of Common Stock included in the Units; (iv) Warrants included in the Units; (v) shares of Series B Preferred included in the Class B Units; (vi) shares of Common Stock underlying the Warrants included in the Units; (vii) shares of Common Stock underlying the shares of Series B Preferred included in the Class B Units; and (viii) any additional securities issued pursuant to Rule 462(b) of the Act.
We have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company and public officials, and other documents as we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such latter documents.
Based upon and subject to the foregoing and to the other qualifications and limitations set forth herein, we are of the opinion that the Securities have been duly authorized, and if, as, and when issued by the Company in accordance with and in the manner described in prospectus set forth in the Registration Statement (as amended and supplemented through the date of issuance) and, in the case of those Securities underlying Warrants and shares of Series B Preferred, when issued in accordance with the terms of the applicable Warrants and Series B Preferred, will be validly issued, fully paid and non-assessable and, with respect to the Warrants, will be legally binding obligations of the Company in accordance with their terms except: (a) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or at law); (b) as enforceability of any indemnification or contribution provision may be limited under the Federal and state securities laws; and (c) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.
Without limiting any of the other limitations, exceptions and qualifications stated elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the Delaware General Corporation Law (based solely upon our review of a standard compilation thereof) as in effect as of the date hereof. This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this opinion letter.
We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to our firm under "Legal Matters" in the related Prospectus. In giving the foregoing consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Securities and Exchange Commission.
Very truly yours,
/s/ SICHENZIA ROSS FERENCE KESNER LLP
1185 Avenue of the Americas | 37th Floor | New York, NY | 10036 T (212) 930 9700 | F (212) 930 9725 | www.srfkllp.com |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 MEF filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended of Aytu BioScience, Inc. (the “Company”) of our report dated August 31, 2017, with respect to the consolidated balance sheets of the Company as of June 30, 2017 and 2016, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the years then ended and to the reference to us under the caption “Experts” which is contained in the Prospectus, which is a part of the Registration Statement (No. 333-222994) on Form S-1 declared effective on March 1, 2018.
/s/ EKS&H LLLP
March 1, 2018
Denver, Colorado